Molecular Partners (MOLN) investor relations material

Executive summary

• Radiotherapeutics and Radio-DARPins are the strategic priority, with isotope selection matched to target biology and vector design; DARPins and Switch-DARPins may also be pursued through partnerships or spin-outs.

• MP0712, a DLL3-targeted ²¹²Pb therapy, leads the clinical portfolio; early Phase 1 safety supported dose escalation, with efficacy data expected in 2027.

• MP0714 provides a ²²⁵Ac DLL3 option; MP0726 targets MSLN and MP0730 targets CD70, broadening the Radio-DARPin pipeline.

Financial highlights

• Cash and cash equivalents were CHF 57.5 million (USD ~69 million) as of September 30, 2026.

Outlook and guidance

• FY 2026 operating expenses are forecast at CHF 50–55 million at constant exchange rates, including ~CHF 5 million of non-cash share-based payment, IFRS pension accounting and depreciation costs.

• Current cash is expected to fund operating expenses and capital expenditures into late 2027, based on current operating assumptions.

• MP0712 DL2 at 105 MBq was fully recruited, with dosing ongoing; initial safety data are expected in December 2026 and efficacy data in 2027.

• MP0726 is progressing to first-in-human imaging in H2 2026; Phase 1 advancement depends on imaging results and therapeutic index.

• MP0730 lead-candidate/preclinical work was planned for H2 2026, with first-in-human studies anticipated in mid-2027.